Bookmark

Add to MyYahoo RSS

Amgen News

News on Amgen (Ticker: AMGN) continually updated from thousands of sources around the net.

53 min ago | AmericanBankingNews.com

Amgen (AMGN) Set to Announce Quarterly Earnings on Tuesday

Amgen is scheduled to be announcing its earnings results on Tuesday, April 22nd.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry

Sun Apr 20, 2014

Ventura County Star

Thousand Oaks needs volunteers for Amgen Tour

The Amgen Tour of California is five weeks away from rolling into Thousand Oaks, and local organizers are looking for volunteers.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Thousand Oaks (Thousand Oaks, CA)

Thu Apr 17, 2014

Business Journal

Biotech VC Column Group seeks $250M to target more big ideas

The Column Group, the David Goeddel -led VC firm whose investments include up-and-coming companies like Igenica Biotherapeutics, Immune Design Corp. and NGM Biopharmaceuticals Inc., has raised $176 million toward a projected $250 million fund.

Comment?

The Motley Fool

Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.

Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Financial Markets

Wed Apr 16, 2014

Hispanic Business

Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In ...

Results showed that, while the primary end point of durable response rate was met , the secondary endpoint of OS was not met, although there was a strong trend in favor of talimogene laherparepvec .

Comment?

Related Topix: Biotech, Amgen, Medicine, Healthcare Industry

Seeking Alpha

Gilead: This Baby Has Been Thrown Away With The Bathwater

The Biotech sector has been under severe pressure lately and it seems to make the "headlines" daily as the cause for so much of the NASDAQ weakness.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Financial Markets, Celgene

Tue Apr 15, 2014

The Motley Fool

Are Biotechs Bad Medicine for the S&P 500?

Specifically, the S&P 500 is now down over 2% in the last month, although it's still up about 15% over the last year.

Comment?

Related Topix: Financial Markets

Mon Apr 14, 2014

GantDaily.com

Biotech firms, investors biding time for breakthrough drugs

New York, NY, United States - Many biotech firms are now biding their time, waiting for their research projects to result in a breakthrough drug that will not only cure a once untreatable disease but could also make the company more profitable.

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Amgen, Healthcare Industry, Gilead Sciences, Startups, CGI Pharmaceuticals

Business Journal

What adding a women's race to Amgen Tour means for Sacramento

The 2014 Amgen Tour of California cycling race adding professional women's cycling in Sacramento and Folsom will contribute to what is already a significant economic impact.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Sacramento, CA, California

Sun Apr 13, 2014

The San Diego Union-Tribune

Partner at Domain seeks out innovators

Kim Kamdar of Domain Associates says the company is excited about biotech and medical device companies in the effort to tailor medicine to specific patients.

Comment?

Related Topix: Amylin Pharmaceuticals, Biotech, Medicine, Healthcare Industry

Fri Apr 11, 2014

The Motley Fool

Are Celgene and Amgen Undervalued By the Market?

The market correction continues to test investor resolve, but longtime market watchers know that sometimes, the best money-making decisions come from buying great stocks at great prices.

Comment?

Related Topix: Celgene, Financial Markets

Thu Apr 10, 2014

Barron's

Biotech: Like Lambs to the Slaughter

The iShares Nasdaq Biotech ETF fell 5.6% to $221.89 today, while the SPDR S&P Biotechnology ETF dropped 6.5% to $129.79.

Comment?

Related Topix: Biotech, Science / Technology, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Celgene

I-Newswire.com

Small Interest Rises As Biotechs Fall

In a period when many biotech stocks were slipping, short sellers moved on many of the leading biotech and emerging pharmaceuticals between the March 14 and March 31 settlement dates.

Comment?

Related Topix: Biotech, Science / Technology, Financial Markets, Medicine, Amgen, Healthcare Industry, Celgene

Reuters

French plan to push copycat biotech drugs worries Big Pharma

France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

Comment?

Related Topix: Medicine

Tue Apr 08, 2014

Business Journal

Amgen breaks off deal with Glaxo for osteoporosis drug

Drug giant Amgen Inc. will pay GlaxoSmithKline $290 million to end a marketing agreement the two companies have in relation to osteoporosis drug Prolia.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Osteoporosis, Health, GlaxoSmithKline, Marketing

Sun Apr 06, 2014

Ventura County Star

Cyclists ride in course replicating final Amgen Tour stage

GARRETT COMBS/ SPECIAL TO THE STAR Ben Collins visits with his cycling group, Amgen, after completing the 80-mile L'Etape du California, which started and finished in Westlake Village on Sunday.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, California, Thousand Oaks, CA, Westlake Village (Thousand Oaks, CA), Westlake Village, CA

Sat Apr 05, 2014

The Motley Fool

This Week in Biotech: Data Disappointments Come in Threes

With the SPDR S&P Biotech Index up 37% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector.

Comment?

Related Topix: Alzheimer's, Health, Healthcare Law, Law, Pancreatic Cancer, Medicine, Diabetes, Food and Drug Administration

Fri Apr 04, 2014

Customer Interaction Solutions

Stocks finish in the red

Via Acquire Media NewsEdge) Energy up, health-care sinks WEEKLY MARKET WRAP UP North American stock markets dropped into negative territory Friday afternoon as traders soured to the latest U.S. jobs figures.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, North American Scientific, Medical Equipment, Healthcare Industry, Amgen

Barron's

Intercept Pharmaceuticals: Too Much Selling Going On

Shares of Intercept Pharmaceuticals have dropped 8.3% to $295, lagging the 3.3% drop in the iShares Nasdaq Biotechnology ETF and the 4.7% decline in the SPDR S&P Biotech ETF .

Comment?

Related Topix: Intercept Pharmaceuticals, Biotech, Startups, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry, Amgen

Benzinga

Amgen Spiking Lower 1.5%, Says Primary Endpoint of Durable...

Amgen today announced top-line results from the primary overall survival analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor .

Comment?

Related Topix: Biotech, Amgen, Healthcare Industry, Skin Cancer, Health

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••
•••